Friday, 16 October 2026European Markets

FRONTLINE, DNO, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Energy Sector.

Loading stream...

(VIANEWS) - FRONTLINE (FRO.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Energy sector.

Financial Asset Price Forward Dividend Yield Return on Equity
FRONTLINE (FRO.OL) kr247.35 10.59% 33.1%
DNO (DNO.OL) kr11.46 9.94% 19.33%
PANORO ENERGY (PEN.OL) kr31.20 2.92% 21.81%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. FRONTLINE (FRO.OL)

10.59% Forward Dividend Yield and 33.1% Return On Equity

Frontline plc, a shipping company, engages in the seaborne transportation of crude oil and oil products worldwide. It owns and operates oil and product tankers. As of December 31, 2022, the company operated a fleet of 70 vessels. It is also involved in the charter, purchase, and sale of vessels. The company was founded in 1985 and is based in Limassol, Cyprus.

Earnings Per Share

As for profitability, FRONTLINE has a trailing twelve months EPS of kr42.05.

PE Ratio

FRONTLINE has a trailing twelve months price to earnings ratio of 5.88. Meaning, the purchaser of the share is investing kr5.88 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.1%.

Growth Estimates Quarters

The company's growth estimates for the present quarter is 309.7% and a drop 3.6% for the next.

More news about FRONTLINE.

2. DNO (DNO.OL)

9.94% Forward Dividend Yield and 19.33% Return On Equity

DNO ASA engages in the exploration, development, and production of oil and gas assets in the Middle East, the North Sea, and West Africa. Its flagship project is the Tawke field that is located in the Kurdistan region of Iraq. The company was founded in 1971 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, DNO has a trailing twelve months EPS of kr2.68.

PE Ratio

DNO has a trailing twelve months price to earnings ratio of 4.28. Meaning, the purchaser of the share is investing kr4.28 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.33%.

Sales Growth

DNO's sales growth for the next quarter is negative 27.5%.

More news about DNO.

3. PANORO ENERGY (PEN.OL)

2.92% Forward Dividend Yield and 21.81% Return On Equity

Panoro Energy ASA, an independent exploration and production company, engages in the exploration, development, and production of oil and gas properties in Africa. It holds assets in the Equatorial Guinea, Gabon, Tunisia, and South Africa. The company was incorporated in 2009 and is based in London, the United Kingdom.

Earnings Per Share

As for profitability, PANORO ENERGY has a trailing twelve months EPS of kr4.14.

PE Ratio

PANORO ENERGY has a trailing twelve months price to earnings ratio of 7.54. Meaning, the purchaser of the share is investing kr7.54 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.81%.

Sales Growth

PANORO ENERGY's sales growth is negative 23.9% for the present quarter and 90.3% for the next.

More news about PANORO ENERGY.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com